Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACLX |
---|---|---|
09:32 ET | 12064 | 52.05 |
09:34 ET | 977 | 51.96 |
09:36 ET | 750 | 52.48 |
09:39 ET | 200 | 52.4 |
09:41 ET | 26158 | 53.355 |
09:43 ET | 200 | 53.38 |
09:45 ET | 600 | 53.85 |
09:48 ET | 307 | 53.31 |
09:50 ET | 518 | 53.2 |
09:52 ET | 300 | 53.53 |
09:54 ET | 800 | 53.84 |
09:56 ET | 7000 | 53.86 |
09:57 ET | 4346 | 54.225 |
09:59 ET | 982 | 54.37 |
10:01 ET | 1737 | 54.56 |
10:03 ET | 100 | 54.68 |
10:06 ET | 2700 | 54.72 |
10:08 ET | 3262 | 54.86 |
10:10 ET | 1200 | 54.885 |
10:12 ET | 2630 | 54.7425 |
10:14 ET | 5963 | 54.13 |
10:15 ET | 1200 | 54.315 |
10:17 ET | 300 | 54.29 |
10:19 ET | 1737 | 54.715 |
10:21 ET | 900 | 54.65 |
10:24 ET | 1009 | 54.57 |
10:26 ET | 2000 | 54.19 |
10:28 ET | 2715 | 53.99 |
10:30 ET | 540 | 54.38 |
10:32 ET | 1345 | 54.17 |
10:33 ET | 606 | 53.9 |
10:37 ET | 700 | 53.97 |
10:39 ET | 1300 | 54.03 |
10:42 ET | 2734 | 53.89 |
10:46 ET | 433 | 53.88 |
10:48 ET | 1400 | 54.095 |
10:50 ET | 4614 | 54 |
10:51 ET | 2500 | 54.42 |
10:53 ET | 900 | 54.44 |
10:55 ET | 1739 | 54.38 |
10:57 ET | 300 | 54.47 |
11:00 ET | 800 | 54.43 |
11:02 ET | 500 | 54.55 |
11:04 ET | 1200 | 54.23 |
11:06 ET | 400 | 54.32 |
11:08 ET | 602 | 54.41 |
11:09 ET | 600 | 54.4 |
11:11 ET | 400 | 54.47 |
11:13 ET | 600 | 54.41 |
11:15 ET | 200 | 54.47 |
11:18 ET | 2000 | 54.31 |
11:20 ET | 218 | 54.17 |
11:22 ET | 156 | 54.22 |
11:24 ET | 300 | 54.28 |
11:26 ET | 400 | 54.16 |
11:27 ET | 2300 | 54.47 |
11:29 ET | 1600 | 54.4 |
11:31 ET | 500 | 54.28 |
11:33 ET | 500 | 54.145 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Arcellx Inc | 2.8B | -52.1x | --- |
IDEAYA Biosciences Inc | 2.8B | -19.4x | --- |
Janux Therapeutics Inc | 2.8B | -44.7x | --- |
Arvinas Inc | 2.3B | -5.3x | --- |
Xenon Pharmaceuticals Inc | 2.9B | -14.5x | --- |
Rhythm Pharmaceuticals Inc | 2.2B | -8.4x | --- |
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $131.7M |
Shares Outstanding | 53.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.04 |
Book Value | $9.28 |
P/E Ratio | -52.1x |
Price/Sales (TTM) | 21.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -57.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.